摘要
目的探析卡托普利联合丹参酮治疗急性发作期肺源性心脏病(肺心病)的疗效。方法 80例急性发作期肺心病患者,随机分为观察组与对照组,各40例。两组患者均给予常规对症疗法,对照组患者给予卡托普利治疗,观察组患者在对照组基础上加用丹参酮治疗,对比两组治疗效果及不良反应情况。结果经治疗,观察组患者总有效率为97.5%,明显高于对照组的82.5%,差异具有统计学意义(χ~2=5.000,P<0.05)。观察组患者不良反应发生率为7.5%,与对照组的2.5%比较,差异无统计学意义(χ~2=1.053,P>0.05)。两组患者的不良反应均较为轻微,未经处理即缓解。结论卡托普利联合丹参酮治疗急性发作期肺心病疗效确切,用药安全性高,值得推广。
Objective To investigate the efficacy of captopril combined with tanshinone in the treatment of acute attack of pulmonary heart disease. Methods A total of 80 patients with acute attack of pulmonary heart disease were randomly divided into observation group and control group, with 40 cases in each group. Both groups received conventional symptomatic treatment, and the control group received captopril for treatment. The observation group received tanshinone on the basis of the control group. Treatment effect and adverse reactions in two groups were compared. Results After treatment, the observation group had obviously higher total effective rate as 97.5% than 82.5% in the control group, and the difference was statistically significant（χ^2=5.000, P〈0.05）. The observation group had no statistically significant difference in incidence of adverse reactions as 7.5%, comparing with 2.5% in the control group（χ^2=1.053, P〉0.05）. The adverse reactions in the two groups were mild and alleviated without treatment. Conclusion Combination of captopril and tanshinone provides affirmative efficacy in treating acute attack of pulmonary heart disease with high medication safety, and it is worth popularizing.
作者
曾志明
ZENG Zhi-ming.(Dongguan City Nancheng Hospital, Dongguan 523073, Chin)
出处
《中国实用医药》
2017年第28期99-100,共2页
China Practical Medicine
